GLP-1 receptor agonists

A current weight-loss and diabetes drug has become a surprise candidate for effective migraine treatment, with a new study showing that the GLP-1 receptor agonist provided significant relief to sufferers of these debilitating, severe headaches.

Remarkable new findings about the sugar stores in neurons have unlocked an entire new method of treating cognitive decline, and it furthers our understanding of why GLP-1 weight loss drugs appear to provide a shield against Alzheimer's disease.

A new drug from pharma company Amgen shows promise as a powerful treatment for obesity. With just a once-monthly shot of 'MariTide,' participants in the study lost as much as 16% of their body weight over the course of a year.

A novel weight loss drug in the same class as semaglutide has successfully met its targets in the largest clinical trial yet, with nearly 90% of participants losing at least 5% of their body weight. The results strengthen its case for FDA approval.

The first clinical trial comparing semaglutide and tirzepatide, two popular, injectable weight-loss drugs, has been published, examining their ability to reduce weight and waist circumference. And one clearly comes out on top.

The first once-daily oral GLP-1 medication could be on shelves by this time next year, making the weight-loss drug easier to take and potentially cheaper. In the race to be the first, Novo Nordisk has scored a huge win, while Pfizer has failed again.

GLP-1 drugs have reportedly changed people's relationship with more than just food, but it's been largely anecdotal. Now, there's evidence that Ozempic blocks alcohol cravings – which could be a game-changer for people who want to cut back on booze.

There's a growing body of evidence that gold nanoparticles can trigger significant weight loss that targets fat, without affecting muscles, plus heal organs and improve blood-glucose levels. A new study makes a strong case for the first-ever human trial.

Scientists remain puzzled as to why some people taking popular weight loss and diabetes medications like Ozempic and Wegovy are losing their vision suddenly, highlighting that there's still so much we don't know about this life-changing class of drugs.

If you're one of the 13% of US adults who has taken a GLP-1 drug for weight loss, you may know that while fat seemingly melts away, so too does muscle. And, so far, there's not a lot you can do about it. But one new discovery may change this.

Nearly half of US adults admit they’d take one of the newer, injectable weight loss drugs; that number falls significantly when they learn the weight might come back when the meds are stopped. It’s something that has medical professionals concerned.

Studies presented at a recent American Heart Association conference have confirmed the heart health benefits provided by the new anti-obesity drugs, semaglutide and tirzepatide, and how lifestyle interventions for weight loss affect heart biomarkers in diabetics.